Generate:Biomedicines Partners with Novartis for the Discovery of Protein Therapeutics in Various Indications
Shots:
- Generate:Biomedicines has signed a multi-target collaboration with Novartis for the discovery and development of undisclosed no. protein therapeutics for various undisclosed indications
- The partnership will integrate The Generate Platform's (Generate's AI platform) machine learning and experimental validation with Novartis' knowledge in target biology, biologics & clinical development to develop novel therapeutics and expedite drug discovery
- Generate will get a total $65M upfront (incl. $15M in equity), >$1B performance-based milestones and low double-digits tiered royalties
Ref: Generate:Biomedicines | Image: Generate:Biomedicines & Novartis
Related News:- Novartis Reports the US FDA’s Approval of Kisqali (Ribociclib) for the Treatment of HR+/HER2- Early Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
